Fosun Pharma sells 6% stake in Gland Pharma via open market
- Fosun Pharma Industrial Pte. Ltd. sold 98,97,000 Gland Pharma shares via open market
- The 6.00% stake disposal was executed on September 4, 2026
- Promoter holding falls from 51.76% to 45.76% of voting capital
- Diluted stake reduces from 51.36% to 45.41%
- Total equity capital remains at 1,64,966,661 shares
*this image is generated using AI for illustrative purposes only.
Gland Pharma promoter Fosun Pharma Industrial Pte. Ltd. has disposed of 98,97,000 equity shares, representing 6.00% of the company’s voting capital, through an open market transaction executed on September 4, 2026.
Transaction details
The disposal was disclosed to stock exchanges on September 8, 2026, in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The sale reduces Fosun Pharma’s holding from 51.76% to 45.76%.
| Parameter | Details |
|---|---|
| Seller | Fosun Pharma Industrial Pte. Ltd. |
| Target company | Gland Pharma Limited |
| Shares sold | 98,97,000 |
| Stake sold | 6.00% (voting capital) |
| Transaction mode | Open market |
| Date of transaction | September 4, 2026 |
| Disclosure date | September 8, 2026 |
Shareholding pattern
Prior to the transaction, Fosun Pharma held 8,53,93,894 shares, constituting 51.76% of the total share/voting capital and 51.36% of the diluted share/voting capital. Following the sale, its holding stands at 7,54,96,894 shares, or 45.76% of the voting capital and 45.41% of the diluted capital.
The total equity share capital of Gland Pharma remained unchanged at 1,64,966,661 equity shares of ₹1 each. The total diluted share/voting capital is 1,66,262,312 equity shares of ₹1 each.
No shares were encumbered with pledge, lien, or non-disposal undertaking before or after the transaction.
Historical Stock Returns for Gland Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.69% | +2.36% | +13.56% | +76.98% | +56.10% | -25.91% |
Will Fosun Pharma initiate further open market sales to reduce its stake below the 45% threshold, potentially triggering additional regulatory disclosures or market volatility?
How might this reduction in promoter holding impact Gland Pharma's credit rating and future ability to secure debt financing for expansion?
Could this stake sale signal a strategic shift in Fosun Pharma's portfolio management, indicating a potential exit or reduced commitment to the Indian generics market?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
